Takeda Seeks To Buy Development, Marketing Rights For New Drugs (Japan)
This article was originally published in PharmAsia News
Executive Summary
Looking ahead to 2010, Takeda Pharmaceutical is counting the costs of developing a drug from scratch and looking to partner with other companies for compounds in at least five areas. President Yasuchika Hasegawa says many of its primary drugs face patent expirations, so the firm is looking to buy development and marketing rights for new drugs in areas where the firm's pipeline is lacking, in depression and schizophrenia and irritable bowel syndrome. One urgent quest of Takeda is to find outside sources for lipid-lowering agents since its own TAK-475 faces concerns about side affects. (Click here for more - may require subscription
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.